Jpmorgan Chase & CO Lexicon Pharmaceuticals, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 90,426 shares of LXRX stock, worth $109,415. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,426
Previous 90,136
0.32%
Holding current value
$109,415
Previous $216,000
30.09%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LXRX
# of Institutions
130Shares Held
240MCall Options Held
617KPut Options Held
286K-
Artal Group S.A. Luxembourg, N4175MShares$212 Million18.64% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$12 Million0.0% of portfolio
-
Braidwell LP Stamford, CT8.29MShares$10 Million0.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.68MShares$9.29 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.85MShares$7.07 Million0.24% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $228M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...